Vamotinib is a tyrosine kinase inhibitor and an antineoplastic. Vamotinib is a novel TKI developed with the specifications of (i) targeting T315I and other resistance mutations in BCR/ABL; (ii) achieving a high selectivity to improve safety; and (iii) overcoming nonmutational resistance in Ph+ leukemias. Vamotinib has potential with the treatment of resistant Ph+ leukemia.
MedKoo Cat#: 121104
Name: Vamotinib
CAS#: 1416241-23-0 (free base)
Chemical Formula: C29H27F3N6O
Exact Mass: 532.2198
Molecular Weight: 532.57
Elemental Analysis: C, 65.40; H, 5.11; F, 10.70; N, 15.78; O, 3.00
The following data is based on the product molecular weight 532.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
